Upside case
Bull case
$124+144.8%
RPRX would need investors to value it at roughly 25x earnings — about 15x more generous than today's 10x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Royalty Pharma plc (RPRX) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
11
analysts
11 bullish · 0 bearish · 11 covering RPRX
Strong Buy
0
Buy
11
Hold
0
Sell
0
Strong Sell
0
Consensus Target
$54
+6.0% vs today
Scenario Range
$11 – $124
Model bear to bull value window
Coverage
11
Published analyst ratings
Valuation Context
10.4x
Forward P/E · Market cap $21.7B
RPRX price targets
Three scenarios for where RPRX stock could go
Current
~$51
Confidence
28 / 100
Updated
May 1, 2026
Where we are now
Current · $51
Bear
$11
Base
$65
Bull
$124
Market caseClosest to today
Base case
$65+27.6%
At 13x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$11-78.8%
If investor confidence fades or macro conditions deteriorate, a 8x multiple contraction could push RPRX down roughly 79% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Royalty Pharma plc
RPRX · NASDAQHealthcareBiotechnologyDecember year-end
Royalty Pharma is a specialized investment firm that acquires royalty interests in approved and development-stage biopharmaceutical products. It generates revenue primarily from royalty payments on approximately 35 marketed therapies — with its largest assets including cystic fibrosis drug Trikafta and HIV treatment Biktarvy — which provide predictable cash flows. The company's competitive advantage lies in its deep expertise in valuing complex biopharmaceutical royalties and its extensive industry relationships that provide access to proprietary deal flow.
Market Cap
$21.7B
Revenue TTM
$2.4B
Net Income TTM
$828M
Net Margin
33.9%
RPRX Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
75%Exceptional
12 quarters tracked
Revenue Beat Rate
17%Exceptional
vs consensus estimates
Avg EPS Surprise
+9.6%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Last 4 Quarters
EPS beats: 4 of 4Q2 2025
EPS
$1.06/$0.95
Revenue
$568M/$705M
Q3 2025
EPS
$1.14/$1.03
Revenue
$579M/$673M
Q4 2025
EPS
$1.17/$0.99
Revenue
$609M/$717M
Q1 2026
EPS
$1.46/$1.29
Revenue
$874M/$807M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q2 2025 | $1.06/$0.95 | +11.2% | $568M/$705M | -19.4% |
| Q3 2025 | $1.14/$1.03 | +10.7% | $579M/$673M | -14.0% |
| Q4 2025 | $1.17/$0.99 | +17.7% | $609M/$717M | -15.1% |
| Q1 2026 | $1.46/$1.29 | +13.2% | $874M/$807M | +8.3% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$2.6B
+10.1% YoY
FY2
$2.7B
+4.2% YoY
EPS Outlook
FY1
$2.04
+49.2% YoY
FY2
$2.27
+11.4% YoY
Trailing FCF (TTM)$2.6B
FCF Margin: 107.0%
Next Earnings
May 6, 2026
Expected EPS
$1.22
Expected Revenue
$906M
RPRX beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
RPRX Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $2.4B
Product Mix
Latest annual revenue by segment or product family
Financial Royalty Assets
95.1%
+5.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Segment breakdown not available for this company.
Financial Royalty Assets is the largest disclosed segment at 95.1% of FY 2025 revenue, up 5.2% YoY.
RPRX Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Undervalued
Fair value est. $74 — implies +49.2% from today's price.
Upside to Fair Value
49.2%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
RPRX
28.2x
vs
S&P 500
25.2x
+12% premium
vs Healthcare Trailing P/E
RPRX
28.2x
vs
Healthcare
22.1x
+27% premium
vs RPRX 5Y Avg P/E
Today
28.2x
vs
5Y Average
19.2x
+46% premium
Forward PE
10.4x
S&P 500
19.1x
-46%
Healthcare
19.0x
-46%
5Y Avg
—
—
Trailing PE
28.2x
S&P 500
25.2x
+12%
Healthcare
22.1x
+27%
5Y Avg
19.2x
+46%
PEG Ratio
3.99x
S&P 500
1.75x
+129%
Healthcare
1.52x
+162%
5Y Avg
—
—
EV/EBITDA
19.2x
S&P 500
15.3x
+26%
Healthcare
14.1x
+36%
5Y Avg
26.6x
-28%
Price/FCF
8.7x
S&P 500
21.3x
-59%
Healthcare
18.7x
-53%
5Y Avg
7.2x
+21%
Price/Sales
9.1x
S&P 500
3.1x
+192%
Healthcare
2.8x
+221%
5Y Avg
7.6x
+20%
Dividend Yield
1.33%
S&P 500
1.88%
-29%
Healthcare
1.40%
-5%
5Y Avg
2.00%
-33%
| Metric | RPRX | S&P 500 | Healthcare | 5Y Avg RPRX |
|---|---|---|---|---|
| Forward PE | 10.4x | 19.1x-46% | 19.0x-46% | — |
| Trailing PE | 28.2x | 25.2x+12% | 22.1x+27% | 19.2x+46% |
| PEG Ratio | 3.99x | 1.75x+129% | 1.52x+162% | — |
| EV/EBITDA | 19.2x | 15.3x+26% | 14.1x+36% | 26.6x-28% |
| Price/FCF | 8.7x | 21.3x-59% | 18.7x-53% | 7.2x+21% |
| Price/Sales | 9.1x | 3.1x+192% | 2.8x+221% | 7.6x+20% |
| Dividend Yield | 1.33% | 1.88% | 1.40% | 2.00% |
RPRX trades above S&P 500 benchmarks on 4 of 6 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolRPRX Financial Health
Verdict
Strong
RPRX generates $2.6B in free cash flow at a 107.0% margin — returns 7.0% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$2.4B
Revenue Growth
TTM vs prior year
+7.8%
Gross Margin
Gross profit as a share of revenue
74.1%
Operating Margin
Operating income divided by revenue
65.1%
Net Margin
Net income divided by revenue
33.9%
EPS (TTM)
Diluted earnings per share, trailing twelve months
—
Free Cash Flow (TTM)
Cash generation after capex
$2.6B
FCF Margin
FCF as share of revenue — the primary cash quality signal
107.0%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
6.7%
ROA
Return on assets, trailing twelve months
4.3%
Cash & Equivalents
Liquid assets on the balance sheet
$619M
Net Debt
Total debt minus cash
$8.3B
Debt Serviceability
Net debt as a multiple of annual free cash flow
3.2× FCF
~3.2 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
8.5%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
7.0%
Dividend
1.3%
Buyback
5.7%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$1.2B
Dividend / Share
Annualized trailing dividend per share
$0.68
Payout Ratio
Share of earnings distributed as dividends
49.1%
Shares Outstanding
Declining as buybacks retire shares
428M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageRPRX Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
High Risk
Pre-Commercial Drug Approval
Royalty Pharma holds pre-commercial drug assets that require regulatory approval before generating revenue. Failure to secure FDA or EMA approval could delay or eliminate expected royalty income, directly impacting future cash flows. The company’s track record shows a high hit rate, but regulatory uncertainty remains a significant risk.
High Risk
Development-Stage Royalty Risk
The company acquires royalties on development-stage product candidates, which may never receive marketing approval. This introduces substantial uncertainty, as these assets could fail in clinical trials or regulatory review, eroding projected revenue streams. The risk is amplified by the high cost of bringing a drug to market.
High Risk
Debt‑Related Risk
Royalty Pharma utilizes borrowed capital to finance acquisitions, increasing its debt burden. Higher leverage raises the likelihood of default and can limit financial flexibility, especially if royalty income declines. The company’s debt levels relative to cash flow are a key metric for assessing default risk.
High Risk
Foreign Currency & Inflation
Revenues and expenses are denominated in multiple currencies; fluctuations against the U.S. dollar can erode earnings. Additionally, high inflation in other countries can increase operating costs, compressing margins. These macroeconomic factors directly affect the company’s profitability.
Medium
Patent Expiration Risk
Royalty streams terminate when underlying patents expire, reducing future cash flows. While the company diversifies across therapeutic areas, a significant portion of its portfolio may face expiration, creating revenue gaps. Managing the timing of new acquisitions is critical to mitigate this risk.
Medium
Exclusivity Litigation Risk
Legal disputes over drug market exclusivity can delay or prevent royalty payments. Litigation outcomes may alter the scope of royalty rights or impose settlement costs, affecting profitability. The biopharma sector’s litigious environment heightens this exposure.
Medium
Premium P/E Ratio Risk
Royalty Pharma’s current P/E ratio exceeds industry and peer averages, suggesting the market may already be pricing in a premium. If future earnings fail to justify this valuation, the stock could experience a correction. Investors should monitor earnings guidance relative to the high valuation.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why RPRX Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Broadening Royalty Portfolio Drives Revenue Growth
Royalty Pharma expects revenue growth as its royalty portfolio expands, providing exposure to drug sales growth while limiting direct development risk. The diversified model funds drug innovation and collects royalties, positioning the company for long‑term value creation.
Strategic $500M Co‑Funding with Johnson & Johnson
The company entered a $500 million R&D co‑funding agreement to advance JNJ‑4804, an autoimmune therapy. This partnership allows Royalty Pharma to deploy capital into high‑value biopharma deals without assuming clinical development risk, enhancing its portfolio mix.
Strong Cash Flow Supports Shareholder Returns
Royalty Pharma generated $2.77 billion in operating cash flow in 2024 and projects 2026 portfolio receipts of $3.275 billion to $3.425 billion. These figures provide ample room to fund new deals while supporting dividends and share buybacks.
EPS Outperformance and 8% Earnings Growth
Q4 2025 earnings per share rose to $1.47, surpassing analyst expectations of $1.33. The company forecasts earnings growth of 8.24% for the coming year, reflecting robust profitability.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
RPRX Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$50.69
52W Range Position
95%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$31.97
+58.6% from the low
52-Week High
$51.65
-1.9% from the high
1 Month
+7.12%
3 Month
+13.53%
YTD
+30.4%
1 Year
+57.9%
3Y CAGR
+12.6%
5Y CAGR
+4.3%
10Y CAGR
+1.3%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
RPRX vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
10.4x
vs 22.3x median
-54% below peer median
Revenue Growth
+10.1%
vs +41.2% median
-75% below peer median
Net Margin
33.9%
vs 61.1% median
-44% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
RPR RPRX Royalty Pharma plc | $21.7B | 10.4x | +10.1% | 33.9% | Buy | +6.0% |
RCU RCUS Arcus Biosciences, Inc. | $2.6B | — | -5.0% | -156.4% | Buy | +15.4% |
OR OR OR Royalties Inc. | $7.3B | 18.9x | +58.0% | 74.3% | Buy | +14.9% |
WPM WPM Wheaton Precious Metals Corp. | $61.1B | 24.8x | +42.4% | 63.6% | Buy | +13.3% |
RGL RGLD Royal Gold, Inc. | $16.4B | 19.9x | +41.2% | 48.5% | Buy | +28.7% |
FNV FNV Franco-Nevada Corporation | $45.2B | 27.1x | +37.5% | 61.1% | Hold | +17.4% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
RPRX Dividend and Capital Return
RPRX returns capital mainly through $1.2B/year in buybacks (5.7% buyback yield), with a modest 1.33% dividend — combining for 7.0% total shareholder yield. The dividend has grown for 5 consecutive years.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
7.0%
Dividend + buyback return per year
Buyback Yield
5.7%
Dividend Yield
1.33%
Payout Ratio
49.1%
How RPRX Splits Its Return
Div 1.33%
Buyback 5.7%
Dividend 1.33%Buybacks 5.7%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.68
Growth Streak
Consecutive years of dividend increases
5Y
3Y Div CAGR
5.0%
5Y Div CAGR
24.0%
Ex-Dividend Date
—
Payment Cadence
Semi-Annual
5 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$1.2B
Estimated Shares Retired
24M
Approx. Share Reduction
5.7%
Shares Outstanding
Current diluted share count from the screening snapshot
428M
At 5.7%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.47 | — | — | — |
| 2025 | $0.88 | +4.8% | 5.7% | 7.4% |
| 2024 | $0.84 | +5.0% | 1.5% | 4.0% |
| 2023 | $0.80 | +5.3% | 1.8% | 3.9% |
| 2022 | $0.76 | +11.8% | 0.0% | 1.9% |
FAQ
7 questionsRPRX Investor Questions
Common questions answered from live analyst data and company financials.
01Is Royalty Pharma plc (RPRX) stock a buy or sell in 2026?
Royalty Pharma plc (RPRX) is rated Buy by Wall Street analysts as of 2026. Of 11 analysts covering the stock, 11 rate it Buy or Strong Buy, 0 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $54, implying +6.0% from the current price of $51. The bear case scenario is $11 and the bull case is $124.
02What is the RPRX stock price target for 2026?
The Wall Street consensus price target for RPRX is $54 based on 11 analyst estimates. The high-end target is $63 (+24.3% from today), and the low-end target is $45 (-11.2%). The base case model target is $65.
03Is Royalty Pharma plc (RPRX) stock overvalued in 2026?
RPRX trades at 10.4x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals significantly undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Royalty Pharma plc (RPRX) stock in 2026?
The primary risks for RPRX in 2026 are: (1) Pre-Commercial Drug Approval — Royalty Pharma holds pre-commercial drug assets that require regulatory approval before generating revenue. (2) Development-Stage Royalty Risk — The company acquires royalties on development-stage product candidates, which may never receive marketing approval. (3) Debt‑Related Risk — Royalty Pharma utilizes borrowed capital to finance acquisitions, increasing its debt burden. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Royalty Pharma plc's revenue and earnings forecast?
Analyst consensus estimates RPRX will report consensus revenue of $2.6B (+10.1% year-over-year) and EPS of $2.04 (+49.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $2.7B in revenue.
06When does Royalty Pharma plc (RPRX) report its next earnings?
Royalty Pharma plc is expected to report its next earnings on approximately 2026-05-06. Consensus expects EPS of $1.22 and revenue of $906M. Over recent quarters, RPRX has beaten EPS estimates 75% of the time.
07How much free cash flow does Royalty Pharma plc generate?
Royalty Pharma plc (RPRX) generated $2.6B in free cash flow over the trailing twelve months — a free cash flow margin of 107.0%. RPRX returns capital to shareholders through dividends (1.3% yield) and share repurchases ($1.2B TTM).